Thyrocare Technologies stock tanks over 7.5% after decline in Q3FY22 PAT and revenue

14 Feb 2022 , 01:22 PM

Thyrocare Technologies’ stock were under pressure in today’s trade as the company reported decline in its revenue owing to covid disruptions. It was currently trading at Rs874.70, down by Rs71.15 or 7.52% against its previous closing price of Rs945.85 on BSE.

Revenue for the quarter ended December 2021 was reported at Rs110.20 crore against Rs132.20 crore for the previous corresponding quarter. Revenue for nine-month ended 31 December 2021 of Rs438 crore grew by 31 % yoy.

EBIDTA was Rs36 crore for Q3FY22 against Rs87.20 crore for Q2FY22, and Rs48.90 crore for Q3FY21, down by 27% yoy and 59% Q0Q.

Company’s PBT was Rs29.10 crore for the current quarter as compared to Rs46 crore for the previous corresponding period, down by 37% yoy. PBT for the previous quarter stood at Rs81.90 crore.

PAT for the current quarter was reported at Rs22.60 crore against Rs34.20 crore for the previous comparable quarter, down by 34% yoy.

Gross Margin settled at 74% for Q3FY22. While EBITDA and PAT margin for the quarter under review was reported at 33% and 21% respectively.